1. Gulyás, B. & Halldin, C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q. J. Nucl. Med. Mol. Imaging 56, 173–190 (2012).
2. Langen, K. J., Galldiks, N., Hattingen, E. & Shah, N. J. Advances in neuro-oncology imaging. Nat. Rev. Neurol. 13, 279–289 (2017).
3. Galldiks, N. & Langen, K. J. Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q. J. Nucl. Med. Mol. Imaging 59, 70–82 (2015).
4. Lopci, E. et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 4, 365–84 (2014).
5. Bouhlel, A. et al. Effect of α-methyl versus α-hydrogen substitution on brain availability and tumor imaging properties of heptanoic [F-18]fluoroalkyl amino acids for positron emission tomography (PET). J. Med. Chem. 59, 3515–3531 (2016).